Alpha Healthcare Acquisition Corp. Warrant (XAGEW)
OTC PINK OTC PINK Primary Summary
Alpha Healthcare Acquisition Corp. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CAK Charles A. Kennedy Carnegie Mellon University | 4,482 | $1.8 | $44.82 | $43.02 | 2,390% |
Alpha Healthcare Acquisition Corp. Warrant (XAGEW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alpha Healthcare Acquisition Corp. Warrant ever had a stock split?
Alpha Healthcare Acquisition Corp. Warrant Profile
| Household Products Industry | Consumer Staples Sector | Janakiram Ajjarapu CEO | OTC PINK Exchange | 142922103 CUSIP |
| US Country | 15 Employees | - Last Dividend | - Last Split | 17 Jul 2023 IPO Date |
Overview
Carmell Corporation, formerly known as Carmell Therapeutics Corporation, represents a forward-thinking shift in the bio-aesthetics industry. Since its founding in 2008, the company has dedicated itself to enhancing skin and hair health through advanced scientific methodologies. Headquartered in Pittsburgh, Pennsylvania, Carmell has solidified its reputation by embracing innovative technologies and forming strategic alliances, including a licensing agreement with Carnegie Mellon University. This partnership focuses on the development and commercialization of biocompatible plasma-based plastics, showcasing Carmell’s commitment to boundary-pushing research and application. A notable milestone in its journey was the rebranding from Carmell Therapeutics Corporation to Carmell Corporation in November 2023, reflecting a broader vision beyond its original therapeutic focus.
Products and Services
- Carmell Secretome for Skin and Hair Health:
At the core of Carmell Corporation's product offerings is the Carmell Secretome, an innovative concoction derived from allogeneic human platelets. This powerful blend of growth factors and proteins, sourced responsibly from tissue banks, has been designed to nurture and support the health of skin and hair, embodying the company's commitment to natural, effective bio-aesthetic solutions.
- Microemulsion Formulation Technology:
Recognizing the potential harms in conventional cosmetic formulations, Carmell has pioneered a microemulsion technology that eschews the Foul Fourteen — a list of 14 excipients deemed potentially harmful due to their texture, stability, and physicochemical effects. This groundbreaking formulation facilitates the delivery of both lipophilic and hydrophilic ingredients without the need for these detrimental excipients, ensuring products are free from mineral or vegetable oils and are non-comedogenic. This development underscores the company’s dedication to safety and efficacy in skincare.
- Men’s Product Line:
With an understanding of the unique dermatological needs of men, Carmell Corporation is in the process of developing a specialized line of products catered specifically to men. This initiative illustrates the company's commitment to inclusivity and its recognition of diverse skincare requirements across its consumer base.
- Topical Haircare Products:
In response to growing demand for effective, non-invasive haircare solutions, Carmell Corporation is expanding its product range to include a line of topical haircare products. Leveraging its expertise in bio-aesthetics and the potent capabilities of the Carmell Secretome, these products are poised to offer innovative solutions for various haircare concerns.
